GET DAILY SIGNALSOption Care Health (OPCH) Delivers Steady Q3 Results Ahead of Major Acquisition
Key Takeaways
- Option Care Health reported third quarter 2026 net revenue of $1.49 billion, up 4.1% year over year and modestly ahead of Wall Street consensus estimates.
- Adjusted diluted earnings per share (EPS) came in at $0.49, in line with analysts' expectations and up 8.9% from the prior-year quarter.
- Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) reached $124.6 million, a 4.3% year-over-year increase.
- GAAP (Generally Accepted Accounting Principles) diluted EPS rose 18.8% to $0.38, while GAAP net income grew 10.8% to $57.4 million.
- The company announced a definitive agreement to be acquired by Clayton, Dubilier & Rice and McKesson Corporation, and as a result withdrew its financial guidance and did not host an earnings call.
- For more context, explore the ticker's Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- Discover actionable market ideas powered by AI by exploring Trending AI Robots.
Understanding the Broader Context
Option Care Health stands as the nation's largest independent provider of home and alternate site infusion services. This space continues to see growth as more complex therapies move from hospitals into lower-cost community settings. The quarterly numbers provide insight into payer reimbursement trends, chronic therapy volumes, and the overall economics of a national pharmacy and infusion network. This report carries extra significance because it coincides with a major corporate development: a pending acquisition by Clayton, Dubilier & Rice and McKesson Corporation. With guidance withdrawn and no earnings call, investors are left to assess the underlying operating performance against the backdrop of a transaction that could alter the company's path forward.
Breaking Down the Reported Figures
For the third quarter ended September 30, 2026, OPCH reported net revenue of $1,493.5 million, an increase of 4.1% from $1,435.0 million in the prior-year period and slightly above consensus estimates near $1.48 billion. GAAP net income rose 10.8% to $57.4 million, translating to GAAP diluted EPS of $0.38, up 18.8% year over year.
On an adjusted basis, diluted EPS was $0.49, matching analysts' consensus expectations and improving 8.9% from $0.45 a year earlier. Adjusted EBITDA increased 4.3% to $124.6 million. Gross profit reached $285.0 million, up from $272.9 million in the same quarter last year, while cash provided by operating activities totaled $114.7 million.
The company also disclosed a definitive merger agreement to be acquired by Clayton, Dubilier & Rice and McKesson Corporation. In connection with the transaction, management withdrew its previously issued financial guidance and suspended its customary earnings conference call, which limited forward-looking commentary.
Market Reaction and Investor Sentiment
Shares of OPCH moved modestly higher right after the release, rising roughly 1.9% as investors digested a revenue beat alongside an in-line adjusted EPS result. The modest top-line outperformance and stable profitability offered some reassurance, though the pending acquisition shaped the larger story. Because the company withdrew guidance and skipped its earnings call, traders had fewer qualitative details to work with, which can heighten uncertainty around the deal's timeline and closing conditions. Sentiment reflects a balance between steady underlying operations and the structural questions that come with a change-of-control transaction.
Forward Outlook and Key Factors to Monitor
Looking ahead, the most significant factor for OPCH shareholders remains the progress and completion of the acquisition by Clayton, Dubilier & Rice and McKesson Corporation. Investors will focus on regulatory approvals, satisfaction of closing conditions, and any updates on transaction timing, as these elements are likely to outweigh near-term operating metrics in driving the stock.
Beyond the deal, several operating themes merit attention. Payer reimbursement rates and therapy mix across acute and chronic portfolios will continue to influence gross margin, which has shown modest year-over-year fluctuation. Volume trends in infusion therapies, along with the company's ability to manage selling, general, and administrative expenses, will shape profitability going forward.
With guidance withdrawn, market participants will need to rely more on industry data and third-party estimates to gauge the company's trajectory. The combination of a solid quarter and a major corporate transaction makes OPCH a name where both operational execution and merger milestones will command close attention in the months ahead. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Exploring AI Tools in My Research Process
When analyzing names like OPCH, I often turn to Tickeron’s AI Screener to quickly filter stocks by technical patterns, fundamentals, and AI-driven signals. It helps me scan across industries and spot comparable ideas without spending hours on manual work, which keeps my research process more efficient while I evaluate both operating results and deal-related developments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
OPCH in upward trend: 10-day moving average crossed above 50-day moving average on October 07, 2026
The 10-day moving average for OPCH crossed bullishly above the 50-day moving average on October 07, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 06, 2026. You may want to consider a long position or call options on OPCH as a result. In 57 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.
OPCH moved above its 50-day moving average on October 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 50-day moving average for OPCH moved above the 200-day moving average on October 29, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +0.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where OPCH advanced for three days, in 174 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.
The Aroon Indicator entered an Uptrend today. In 158 of 221 cases where OPCH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 71%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 20 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Moving Average Convergence Divergence Histogram (MACD) for OPCH turned negative on October 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 33 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OPCH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.
OPCH broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. OPCH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 71 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OPCH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.763) is normal, around the industry mean (204.016). P/E Ratio (23.797) is within average values for comparable stocks, (19.314). Projected Growth (PEG Ratio) (1.101) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.094) among similar stocks. P/S Ratio (0.682) is also within normal values, averaging (2.688).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of home and alternate site infusion services.
Industry HospitalNursingManagement
Advertisement